Swimming legend Emma Igelström is serious about recovery for young athletes

Press releases   •   Nov 20, 2020 15:02 CET

Smartfish Sport is happy to announce its latest collaboration with swimming legend Emma Igelström. Emma is a former Swedish breaststroke swimmer and five times World Champion.

LIPIDS publishes PREPARE study on intervention with Smartfish´ Marine Omega-3 Fatty Acids emulsion demonstrating effect on the follicular fluid for couples awaiting IVF

Press releases   •   Oct 22, 2020 16:23 CEST

The University of Southampton has published another study from the PREPARE (PREconception dietary suPplements in Assisted REproduction) TRIAL investigating the effects of a six-week dietary intervention with Smartfish´ marine omega-3 fatty acids on fertility. The findings demonstrate an altered fatty acid composition of follicular fluid following the 6-week intervention (1).

Alexandra J. Kermack and colleagues conclude that “increased dietary intake of marine omega-3 fatty acids is reflected in an altered fatty acid profile of human follicular fluid with increased amounts of EPA and DHA”. This study is the first to report that a dietary intervention alters the fatty acid composition of follicular fluid in humans and shows the need for further research to determine the potential effects this intervention can have on improved oocyte quality.

The fatty acid composition of human follicular fluid is important for oocyte development and for pregnancy following in vitro fertilization (IVF). Lifestyle and clinical factors have been associated with the composition of follicular fluid, thus, this study investigated whether a six-week dietary intervention with marine omega-3 fatty acids, olive oil, and vitamin D alters the fatty acid composition of human follicular fluid.

A total of 111 couples awaiting IVF or in vitro fertilization-intracytoplasmic sperm injection (IVF-ICSI) were recruited to this double-blinded, randomized controlled trial. The intervention group received olive oil for cooking, an olive oil-based spread, and a daily supplement of Smartfish emulsion enriched with 800 mg EPA (eicosapentaenoic acid), 1200 mg DHA (docosahexaenoic acid), and 10 μg vitamin D. The control group received sunflower seed oil for cooking, a sunflower seed oil-based spread, and a daily supplemental drink without EPA, DHA, or vitamin D.

Dietary questionnaires were completed at baseline and blood samples were collected at baseline and after the six-weeks supplementation period. Follicular fluid was extracted at oocyte retrieval and the fatty acid profile was assessed using gas chromatography.

Results from this study showed higher percentages of EPA and DHA in follicular fluid of women who consumed supplemental drinks containing EPA and DHA compared to the control group. Furthermore, women in the intervention group had lower percentages of the omega-6 fatty acids linoleic acid and arachidonic acid.

The results of the current study (1) together with previous results from the PREPARE trial (2) shed light on some underlying causes of subfertility. The explanation might to some extent be the fatty acid composition of human follicular fluid and its impact on oocyte quality. Targeted dietary supplementation could potentially be a future way to address fertility issues says Mozhgan Dorkhan, Chief Scientific Officer at Smartfish.

For more information, please contact:Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331
Geir Harstad, CEO of Smartfish, + 46 763151160

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice-based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Investinor, an investment company funded by the Norwegian Government, and Industrifonden, an independent Swedish early phase investment foundation.

1.Kermack AJ, Wellstead SJ, Fisk HL, Cheong Y, Houghton FD, Macklon NS, et al. The Fatty Acid Composition of Human Follicular Fluid Is Altered by a 6-Week Dietary Intervention That Includes Marine Omega-3 Fatty Acids. Lipids. 2020.

2.Kermack AJ, Lowen P, Wellstead SJ, Fisk HL, Montag M, Cheong Y, et al. Effect of a 6-week "Mediterranean" dietary intervention on in vitro human embryo development: the Preconception Dietary Supplements in Assisted Reproduction double-blinded randomized controlled trial. Fertil Steril. 2020;113(2):260-9.

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

The University of Southampton has published another study from the PREPARE (PREconception dietary suPplements in Assisted REproduction) TRIAL investigating the effects of a six-week dietary intervention with Smartfish´ marine omega-3 fatty acids on fertility. The findings demonstrate an altered fatty acid composition of follicular fluid following the 6-week intervention (1).

Read more »

Press release: Smartfish partners with the international Public-Private Consortium P4O2 (Precision Medicine for More Oxygen) investigating risk factors for developing lung damage and chronic complaints after COVID-19

Press releases   •   Sep 29, 2020 15:32 CEST

AMSTERDAM, OSLO AND LUND, SEPTEMBER 29, 2020.

Many patients who have had COVID-19 continue to have health complaints for a long period of time. The long-term effects of the damage caused by the virus and the body's response to it is unclear. A team of researchers, private parties and patient representatives will investigate how these complaints develop and which factors can predict them in future patients. The project is co-funded by the PPP Allowance made available by Top Sector Life Sciences & Health (Health~Holland).

The Smartfish product Remune™ fororal nutrition is chosen as nutrition intervention in the Post COVID-19 Extension study. Remune™ has marine DHA and EPA fatty acids as important ingredients. The product is a juice-based targeted medical nutrition product and has to date been documented in two multi-centre, double-blinded, randomized controlled clinical trials in cancer and COPD for nutritional management of pre-cachexia and/or cachexia.We are happy to contribute generating new insights on targeted nutritional intervention in post COVID-19 management, says Smartfish CSO Mozhgan Dorkhan.

Patients who have been admitted to hospital because of COVID-19 and those who consulted their GP after remaining ill for a long time after COVID-19, will be referred to a post-corona clinic where lung function tests, CT scans, questionnaires, and laboratory tests will be performed. For this P4O2-COVID study, additional tests will be performed in middle-aged patients when they visit the clinic approximately 3 and 12 months after their initial recovery from COVID-19.

State-of-the-art measurements and analyzes that are applied within renowned scientific studies will be carried out in the 100 people participating in this study. For example, additional biological samples will be taken to perform various –omics measurements (a method to very extensively map biological and chemical process, for example, gene regulation, metabolism, or bacteria in the body) to gain insight into possible differences in the biological response of patients with long-term complaints. The exposome of these patients will also be mapped. These are environmental and social factors which people experience in daily life, such as chemicals, air pollution, smoking, dietary intake, and physical activity. Participants will receive devices that measure their exposure and physical activity, for example a bracelet that collects substances from the environment. CT scans, which are part of standard care, will be analyzed using the latest artificial intelligence methods. Participants will also be offered an intervention focused on nutrition and physical activity that is expected to have a beneficial effect on quality of life. Furthermore, with the help of experimental cell models, laboratory research will help to identify factors and mechanisms that predict a more serious course of disease. Using big-data analysis, a pattern will be sought in the data that predicts who is susceptible to developing chronic complaints after the disease in future patients.

This research fits the missions of the Top Sector LSH, as there is attention for unhealthy lifestyle and the living environment (mission I) and for care provided to people within their own living environment (mission II). The P4O2-COVID study will reduce the proportion of people with a chronic disease or lifelong disability (mission III).

About the consortium

The P4O2-COVID study will be performed by partners from the P4O2 consortium; this consortium originated from the National Program for Lung Research, which the Netherlands Respiratory Society (NRS) developed together with other lung associations, researchers, healthcare professionals, patients, and companies to generate more attention for lung diseases and to improve cooperation between lung researchers in the Netherlands. Collaboration with industry will promote implementation of the acquired knowledge.

Partners and sponsors of the P4O2 COVID project are Amsterdam UMC, LUMC, UMCG, UMC Utrecht, Utrecht University, Maastricht University and Maastricht UMC+, Boehringer Ingelheim, Breathomix, Fluidda, Novartis, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, and TopMD. The collaboration project is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships (https://www.health-holland.com). The consortium is led by Prof. Dr. Anke-Hilse Maitland - van der Zee from the Amsterdam UMC, location AMC. More information is available at www.p4o2.org and via nrs@nrs-science.nl

For more information, please contact

Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331

Geir Harstad, CEO of Smartfish, tel + 46 763151160

About Smartfish AS

Smartfish AS is active within research, development, production and marketing of advanced clinically documented nutritional drinks in the field of medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice-based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway and Lund, Sweden. Smartfish’s main shareholders are Investinor (Norway) and Industrifonden (Sweden). Learn more on https://www.smartfishnutrition.com.

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Many patients who have had COVID-19 continue to have health complaints for a long period of time. A team of researchers, private parties and patient representatives will investigate how these complaints develop and which factors can predict them in future patients. The project is co-funded by the PPP Allowance made available by Top Sector Life Sciences & Health (Health~Holland).

Read more »

First patient recruited in research study investigating the effects of Remune in combination with exercise in cancer patients

Press releases   •   Sep 10, 2020 14:40 CEST

OSLO, NORWAY AND LUND, SWEDEN, June 29, 2020. Smartfish AS announces today the initiation of a research study at University of Rochester to assess the impact of Remune in combination with exercise on physical function and cachexia-related symptoms in cancer patients. Remune has previously shown to be beneficial in the nutritional management of cancer. The study will include a total of 45 patients.

The main aim of the randomized interventional study is to clarify whether nutritional supplementation containing high levels of omega-3 fatty acids, vitamin D and protein has an effect on cachexia and weight loss in patients suffering from Non-Small Cell Lung Cancer (NSCLC) or gastrointestinal cancer. The study participants will follow a bi-daily regimen of Remune for twelve weeks, with or without a progressive resistance exercise program (EXCAP©), developed specifically for cancer patients. Additionally, the researchers will investigate whether concomitant intake of Remune improves physical performance and quality of life, as well as assess the long-term impact on relevant biomarkers.

“Cancer cachexia is a complex condition that is best managed by multimodal intervention and optimal nutrition is a cornerstone in the management of cancer cachexia. The fact that Smartfish’s Remune is chosen for this important study is a recognition of our high-quality and tasty targeted medical nutrition products that can impact the outcome for severely ill patients”, says Mozhgan Dorkhan, Chief Scientific Officer at Smartfish.

Remune has been used in two randomized, double-blinded, and placebo-controlled pilot trials in patients with COPD and NSCLC with cachexia. In these studies, Remune demonstrated improvement in fatigue and dyspnea and the outcome measures of cancer treatment respectively by enhancing the nutritional status in these patient groups.

To learn more about Smartfish’s trials in NSCLC patients – original study and in-depth analysis – and in COPD patients, please follow the links.


For more information, please contact
Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331
Geir Harstad, CEO of Smartfish, tel + 46 763151160

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Smartfish AS announces today the initiation of a research study at University of Rochester to assess the impact of Remune in combination with exercise on physical function and cachexia-related symptoms in cancer patients. Remune has previously shown to be beneficial in the nutritional management of cancer. The study will include a total of 45 patients.

Read more »

In-depth analysis of clinical trial results shows that Smartfish’s Remune can improve physical performance in pre-cachectic lung cancer patients

Press releases   •   Jun 12, 2020 14:25 CEST

OSLO, NORWAY AND LUND, SWEDEN, June 12, 2020. Smartfish AS today announces positive outcomes following an in-depth analysis of data from a previously conducted clinical trial of RemuneTM, an oral targeted medical nutrition (TMN) supplement, in non-small-cell lung cancer patients. The results from the in-depth analysis was published today in a Letter to the Editor of Nutrition and Cancer and indicates improved physical function in pre-cachectic patients following Remune nutrition intervention.

The in-depth analysis is based on data from a previously published 12-week, double-blinded, comparator-controlled pilot study investigating the safety and tolerability profile of Remune – an oral targeted medical nutrition (TMN) supplement – in patients suffering from non-small-cell lung cancer. This patient group is exposed to an increased risk of developing cachexia, a condition characterized by involuntary weight loss, with subsequent negative impacts on clinical outcomes such as quality of life and survival. In the previously published paper, an exploratory analysis revealed that the pre-cachectic subgroup who received TMN demonstrated fewer side effects and an improved survival in comparison to the comparator group.

The novel findings from the post-hoc analysis indicate that the sub-group of pre-cachectic patients also experienced a significant improvement in physical performance, assessed by the grip strength test – a widely used method to measure forearm muscle function, which has been shown to produce fair predictions of survival in lung cancer patients. The treatment group who received Remune exhibited significantly better performance in both the dominant arm (p=0.0415) and the non-dominant arm (p=0.0146) compared to the control group. The authors conclude that these promising results warrant future studies to evaluate the effects of Remune as nutritional management in a larger population of cancer patients.

“Remune has carefully selected ingredients targeting the underlying mechanisms of cachexia. These coherent and promising results underpin that our high-quality nutritional products play a fundamental role in nutritional management of cancer. For this reason, we are looking forward to collaborating in future comprehensive research studies to further document and develop our medical nutrition products”, says Mozhgan Dorkhan, Chief Scientific Officer at Smartfish.

Remune has so far been successfully documented in two randomized, double-blinded and placebo-controlled safety and tolerability trials addressing pre-cachexia or cachexia in patients with chronic obstructive pulmonary disease (COPD) or non-small-cell lung cancer.

For more information, please contact
Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331
Geir Harstad, CEO of Smartfish, tel + 46 763151160

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Positive outcomes following an in-depth analysis of data from a previously conducted clinical trial of Remune, an oral targeted medical nutrition supplement, in cancer patients. Results from an in-depth analysis was published today in a Letter to the Editor of Nutrition and Cancer and indicates improved physical function in pre-cachectic patients following Remune nutrition intervention.

Read more »

New study reports positive results for Smartfish product in patients with declining cognitive function

Press releases   •   Jun 11, 2020 13:00 CEST

OSLO, NORWAY AND LUND, SWEDEN, June 11, 2020. A new study published today presents positive results from a 6-year-research project at University of California, Los Angeles, where a drink-based nutritional product from Smartfish AS was used as an add-on to pharmacological treatment in patients with declining cognitive function. The results further strengthen evidence that Smartfish’s high quality nutritional products can enhance clinical outcome.

The nutritional drink used in the current study is part of the Smartfish product family and is a juice-based nutritional drink produced with the company’s proprietary emulsion technology containing unique high levels of omega-3-fatty acids, vitamin D, whey protein and resveratrol. In the current study, published [today] in the Journal of Alzheimer’s Disease, researchers at the University of California, Los Angeles (UCLA) have evaluated whether a nutritional drink from Smartfish, in addition to a conventional treatment with cholinesterase inhibitors could delay the disease progression in patients who exhibited cognitive impairment. Results from the study indicate both short-term and long-term positive effects from the combined treatment in patients suffering from mild cognitive impairment, as shown by improvements in cognition and activities of daily living.

“The outcomes of the study are exciting and strengthens our core belief that high quality omega-3-fatty acid supplements in combination with targeted nutritional ingredients can play a role in enhancing the clinical impact of standard medical treatments. There is a growing interest in and understanding of this in the research community and it is encouraging that the researchers continuously choose our products for their studies”, says Mozhgan Dorkhan MD, PhD and Chief Scientific Officer at Smartfish.

“We consider the excellent standard and the composition of nutritional supplementation to be of outmost importance for our patients. Smartfish’s omega-3 drink has had a precise concentration of the essential docosahexaenoic acid as well as excellent maintenance of its quality and efficacy during the full length of our 6-year-long study with patients suffering from early Alzheimer disease”, says Milan Fiala, MD, UCLA.

To date, Smartfish has partaken as a collaborator in some 40 studies showing positive effects from Smartfish products, such as RemuneTM, NutrifriendTM and RechargeTM on metabolic health, mental health and muscle recovery among others.

Beside these collaborative studies, Smartfish has conducted two randomized, double-blinded and placebo-controlled trials where Remune was evaluated as a targeted medical nutritional product in non-small cell lung cancer and chronic obstructive lung disease. Both these clinical trials showed positive effects on patient outcome when Remune was combined with standard care.

A full list of all research studies where Smartfish has participated can be found here.

For more information, please contact
Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331
Geir Harstad, CEO of Smartfish, tel + 46 763151160

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

A new study published today presents positive results from a 6-year-research project at University of California, Los Angeles, where a drink-based nutritional product from Smartfish was used as an add-on to pharmacological treatment in patients with declining cognitive function. The results further strengthen evidence that Smartfish’s high quality nutritional products can enhance clinical outcome.

Read more »

Smartfish initiates Asian rollout of its consumer health products through a new strategic partnership with Jacobson Pharma

Press releases   •   Oct 04, 2019 07:59 CEST

OSLO, NORWAY AND LUND, SWEDEN, OCTOBER 4, 2019. Smartfish AS initiates a rollout of its consumer health nutritional products into new markets in Asia through a new strategic partnership with Jacobson Pharma Group. As a strong sign of commitment to the new partnership, Jacobson Pharma Group recently invested NOK 40 million in Smartfish through a share issue.

Smartfish provides unique nutritional solutions for both medical use and consumer health. The company’s evidence based and tasty nutrition products are based on a proprietary emulsion technology that enables high levels of Omega 3 fatty acids, whey protein and other nutrients.

Jacobson Pharma Corporation Limited (Jacobson Pharma), listed on the Hong Kong stock exchange with annual revenues over 1.7 bn HKD, today distributes Smartfish Cream for children’s brain health in Hong Kong. According to the new agreement Jacobson Pharma Group will distribute and market Smartfish’s entire consumer health portfolio in China, Taiwan, Hong Kong and Macau. The new strategic partnership is initiated by the launch of the products Smartfish Recharge for sport nutrition, Smartfish Reflect for adults’ brain health, Smartfish Resolve for improved metabolism and Smartfish Cream for children’s brain health.

“The Asian markets offer huge growth opportunities for our consumer health products and we are very pleased to strengthen our partnership with Jacobson Pharma. Our recently announced partnership with B. Braun for the global expansion of our medical nutrition products, together with the rollout of our consumer health products in Asia, pave the way for significant value creation in the coming years,” comments Smartfish’s CEO Geir Harstad.

As part of the strengthened collaboration Jacobson Pharma Group recently invested in Smartfish through a share issue. Following the investment, Jacobson Pharma Group has a 9 percent stake in Smartfish.

“We welcome Smartfish’s well documented nutrition products to our consumer health portfolio. We see a great interest in Asia for products that can enhance the capacity of both adults and children, and we believe that our market knowledge, distribution power and network will, together with Smartfish’s technology and development capacity, create important value going forward”, comments Derek Sum, Chairman and CEO, Jacobson Pharma.


For more information, please contact:

Geir Harstad, CEO of Smartfish, tel + 46 763151160

Jens Nordahl, VP Sales & Marketing, tel +47 996 299 99


About Jacobson Pharma Group

Jacobson Pharma Group is a leading pharmaceutical group in Hong Kong providing a wide range of pharmaceutical and consumer health products to the healthcare community including hospitals, clinics, physicians, pharmacies and drug stores in the Greater China and Asia Pacific regions. With a clearly defined vision of becoming a leading player in the pharmaceutical and consumer health arena within the Greater China and Asia Pacific regions, Jacobson Pharma is well positioned to capitalize the growth opportunities via the unwavering effort of its dedicated workforce.

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Smartfish AS initiates a rollout of its consumer health nutritional products into new markets in Asia through a new strategic partnership with Jacobson Pharma Group. As a strong sign of commitment to the new partnership, Jacobson Pharma Group recently invested NOK 40 million in Smartfish through a share issue.

Read more »

Smartfish starter utrulling av forbrukerhelseprodukter i Asia gjennom et nytt strategisk partnerskap med Jacobson Pharma

Press releases   •   Oct 04, 2019 07:59 CEST

OSLO, NORGE OG LUND, SVERIGE, OCTOBER 4, 2019. Smartfish AS setter i gang en utrulling av sine forbrukerhelseprodukter til nye markeder i Asia gjennom et nytt strategisk partnerskap med Jacobson Pharma Group. Jacobson Pharma Group investerte nylig 40 millioner kroner i Smartfish gjennom en emisjon, et tydelig tegn på selskapets tro på partnerskapet med Smartfish.

Smartfish produserer unike ernæringsløsninger for både medisinsk bruk og forbrukerhelse. Selskapets vitenskapelig baserte og velsmakende ernæringsprodukter er basert på en egenutviklet emulsjonsteknologi som muliggjør høye nivåer av Omega 3-fettsyrer, myseprotein og andre aktive næringsstoffer.

Jacobson Pharma Corporation Limited (Jacobson Pharma), notert på børsen i Hong Kong med årlige inntekter over 1,7 milliarder HKD, distribuerer i dag Smartfish Cream for barns hjernehelse i Hong Kong. I henhold til den nye avtalen vil Jacobson Pharma Group distribuere og markedsføre hele forbrukerhelseporteføljen til Smartfish i Kina, Taiwan, Hong Kong og Macau. Det nye strategiske partnerskapet begynner med lanseringen av produktene Smartfish Recharge sporternæring, Smartfish Reflect for voksnes hjernehelse, Smartfish Resolve for forbedret metabolisme og Smartfish Cream for barns hjernehelse.

"De asiatiske markedene byr på store vekstmuligheter for våre forbrukerhelseprodukter, og vi er veldig glade for å styrke vårt samarbeid med Jacobson Pharma. Vårt nylig annonserte partnerskap med B. Braun for den globale distribusjonen av Smartfish medisinske ernæringsprodukter, sammen med utrullingen av våre forbrukerhelseprodukter i Asia, baner vei for betydelig verdiskapning de kommende årene” kommenterer administrerende direktør i Smartfish, Geir Harstad.

Som en del av det styrkede samarbeidet investerte Jacobson Pharma Group nylig i Smartfish gjennom en emisjon. Som følge av investeringen har Jacobson Pharma Group en eierandel på 9 prosent i Smartfish.

"Vi ønsker Smartfish sine veldokumenterte ernæringsprodukter velkommen til vår forbrukerhelseportefølje. Vi ser stor interesse i Asia for produkter som kan bidra positivt for både voksne og barn, og vi tror at vår markedskunnskap, distribusjonskraft og nettverk sammen med Smartfish sin teknologi og utviklingskapasitet vil skape stor verdi fremover”, kommenterer Derek Sum, styreleder og administrerende direktør i Jacobson Pharma.


For mer informasjon, kontakt:

Geir Harstad, Administrerende Direktør Smartfish, tlf + 46 763151160

Jens Nordahl, VP Sales & Marketing, tlf +47 996 299 99


Om Jacobson Pharma Group

Jacobson Pharma Group er et ledende farmasøytisk konsern basert i Hong Kong som leverer et bredt spekter av farmasøytiske og forbrukerhelseprodukter til helsevesenet, inkludert sykehus, klinikker, leger, apotek og nettbutikker i Stor-Kina og Asia-Stillehavsregionen. Med en tydelig definert visjon om å bli en ledende aktør innen produksjon og distribusjon av legemidler og forbrukerhelseprodukter i Stor-Kina og Asia-Stillehavsregionen, er Jacobson Pharma godt posisjonert for å utnytte vekstmulighetene både på kort og lang sikt. 

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Smartfish AS setter i gang en utrulling av sine forbrukerhelseprodukter til nye markeder i Asia gjennom et nytt strategisk partnerskap med Jacobson Pharma Group. Jacobson Pharma Group investerte nylig 40 millioner kroner i Smartfish gjennom en emisjon, et tydelig tegn på selskapets tro på partnerskapet med Smartfish.

Read more »

Smartfish lanserar sin produktportfölj inom consumer health i Asien genom ett nytt strategiskt samarbete med Jacobson Pharma

Press releases   •   Oct 04, 2019 07:59 CEST

OSLO, NORGE OCH LUND, SVERIGE, 4 OKTOBER 2019. Smartfish AS påbörjar nu en lansering av sina produkter inom consumer health och sportnutrition på den asiatiska marknaden. Lanseringen sker inom ramen för ett nytt strategiskt samarbete med Jacobson Pharma. Som ett led i samarbetet har Jacobson Pharma nyligen investerat 40 miljoner NOK i Smartfish genom en aktieemission, ett tydligt kvitto på Jacobson Pharmas långsiktiga engagemang i Smartfish.

Smartfish erbjuder unika evidensbaserade nutritionsprodukter både för medicinska ändamål och för friska individer som vill förbättra sin hälsa och prestationsförmåga. Produkterna har utvecklats med en patentskyddad emulsionsteknologi som gjort det möjligt att åstadkomma höga nivåer av omega-3-fettsyror, vassleprotein och andra näringsämnen i en välsmakande dryck.

Jacobson Pharma Corporation Limited (Jacobson Pharma) är listade på Hongkongbörsen och har en årlig omsättning på över 1,7 miljarder HKD. Företaget säljer i dag Smartfish Cream i Hongkong, ett kosttillskott för förbättrad kognitiv förmåga hos barn. Det nya avtalet innebär att Jacobson Pharma kommer att marknadsföra och distribuera hela Smartfish portfölj inom consumer health i Kina, Taiwan, Hong Kong och Macau. Samarbetet inleds med lanseringen av produkten Smartfish RechargeTM (för förbättrad muskelåterhämtning), Smartfish ReflectTM (för förbättrad kognitiv förmåga hos vuxna), Smartfish ResolveTM (för förbättrad ämnesomsättning) samt Smartfish CreamTM (för förbättrad kognitiv förmåga hos barn).

– Den asiatiska marknaden erbjuder en enorm tillväxtmöjlighet för våra produkter inom consumer health och vi är mycket glada över att kunna stärka vårt befintliga samarbete med Jacobson Pharma. Nyligen inledde vi även ett samarbete med läkemedelsföretaget B. Braun för en global lansering av våra medicinska nutritionsprodukter. Sammantaget bäddar dessa samarbeten för betydande värdeskapande de kommande åren, säger Geir Harstad, vd Smartfish.

Som en del i det utökade samarbetet investerade Jacobson Pharma Group nyligen i Smartfish genom en aktieemission. Efter investeringen uppgår Jacobson Pharma Groups ägande till 9 procent av Smartfish.

– Vi välkomnar Smartfish väldokumenterade produkter inom consumer health till vår produktportfölj. Vi märker av ett stort intresse i Asien för produkter som kan öka kapaciteten hos både vuxna och barn och vi tror att vår gedigna kunskap om den asiatiska marknaden, våra distributionskanaler och våra upparbetade nätverk, tillsammans med Smartfish teknologi och utvecklingskapacitet, kommer att ha potential att skapa stora värden framöver, säger Derek Sum, styrelseordförande och vd, Jacobson Pharma.

För ytterligare information, vänligen kontakta:

Geir Harstad, vd Smartfish, tel + 46 763151160

Jens Nordahl, försäljning- och marknadsdirektör, tel +47 996 299 99

Om Jacobson Pharma

Jacobson Pharma Group är en ledande aktör inom läkemedelsområdet i Hong Kong och erbjuder en bred portfölj av consumer health och läkemedel till hälso- och sjukvården vilket inkluderar sjukhus, vårdcentraler, apotek och kliniker i Kina och Asien. Med en tydlig vision att bli en ledande aktör inom läkemedel och consumer health i Kina och Asien-Stillahavsregionen är Jacobson Pharma med sina engagerade medarbetare väl positionerat för att kunna tillvarata tillväxtmöjligheterna i hela regionen.

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Smartfish AS påbörjar nu en lansering av sina produkter inom consumer health och sportnutrition på den asiatiska marknaden. Lanseringen sker inom ramen för ett nytt strategiskt samarbete med Jacobson Pharma. Som ett led i samarbetet har Jacobson Pharma nyligen investerat 40 miljoner NOK i Smartfish genom en aktieemission, ett tydligt kvitto på Jacobson Pharmas långsiktiga engagemang i Smartfish.

Read more »

​Smartfish initiates global collaboration with B. Braun, securing forceful launch of its medical nutrition product Remune

Press releases   •   Sep 09, 2019 08:29 CEST

Smartfish AS has initiated a strategic collaboration with the global healthcare company B. Braun to secure a forceful global launch of its medical nutrition product Remune. B. Braun will launch Remune in close to 20 countries during 2019 and 2020, followed by several other markets in Europe, Asia and South America.

Images & Videos 6 images

About Smartfish AS

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Address

  • Smartfish AS
  • Forskningsparken / Oslo Innovation Center, Gaustadalléen 21
  • 0349 Oslo
  • Norge